← Back to Patent Explorer
US4192871A Expired / Lapsed US ⏱️ 0.0 years remaining

Chemical compounds

Assignee: Glaxo Laboratories Ltd
•
Filing: 1978-05-22
•
Granted: 1980-03-11
•
Expires: 1998-05-22
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Pregnanes and androstanes are described which essentially possess a 3α-hydroxy group, a 5α-hydrogen atom or a 4.5- or 5,6-double bond, a 17α-hydrogen atom and an 11β-aminoester group. Other optional substituents or double bonds may be present. The compounds have anaesthetic activity.

Inventors

  • 👤 Gordon H. Phillipps
  • 👤 Peter J. May
  • 👤 Barry E. Ayres

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-01 20:28
CPC Classifications
C; C07; C07J; C07J13/00; C07J13/005; C07J17/00; C07J3/00; C07J3/005; C07J31/00; C07J31/006; C07J41/00; C07J41/0033; C07J41/0088; C07J41/0094; C07J43/00; C07J43/003; C07J5/00; C07J5/0007; C07J5/0015; C07J63/00; C07J7/00; C07J7/0005; C07J7/001; C07J7/0015; C07J7/0025; C07J7/003; C07J71/00; C07J71/0005; C07J71/001

Claims Analysis

Total Claims: 24
Claim 1
Independent Claim 213 words
Steroids of the pregnane and androstane series and their 19-nor analogues having a 3α-hydroxy group; a 5α-hydrogen atom or a 4,5- or 5,6-double bond; a 17α-hydrogen atom; and at the 11β-position a group of the formula R 1 COO- where R 1 is a C 1-6 alkyl group or a monocyclic aralkyl group having a C 1-6 alkyl portion, the alkyl group or alkyl portion being substituted by an amino group of the formula -NR a R b , in which R a and R b , which may be the same or different, are hydrogen atoms, alkyl, alkenyl, cycloalkyl, cycloalkenyl or phenalkyl groups, provided that at least one of R a and R b is other than hydrogen and that R a and R b together contain up to 14 carbon atoms, or in which R a and R b , together with the nitrogen atom, represent a saturated or ethylenically unsaturated non-aromatic monocyclic heterocyclic group having 3-10 ring members or a saturated or unsaturated bicyclic heterocyclic group having up to 10 ring carbon atoms, the ring containing the nitrogen atom being non-aromatic and either saturated or ethylenically unsaturated, which heterocyclic groups may be unsubstituted or substituted by C 1-4 alkyl; the 17aα-hydrogen D-homo analogues thereof; and the acid addition salts thereof.
Claim 2
Dependent Claim 213 words
Steroids of the pregnane and androstane series and their 19-nor analogues having a 3α-hydroxy group; a 5α-hydrogen atom or a 4,5- or 5,6-double bond; a 17α-hydrogen atom; and at the 11β-position a group of the formula R 1 COO- where R 1 is a C 1-6 alkyl group or a monocyclic aralkyl group having a C 1-6 alkyl portion, the alkyl group or alkyl portion being substituted by an amino group of the formula -NR a R b , in which R a and R b , which may be the same or different, are hydrogen atoms, alkyl, alkenyl, cycloalkyl, cycloalkenyl or phenalkyl groups, provided that at least one of R a and R b is other than hydrogen and that R a and R b together contain up to 14 carbon atoms, or in which R a and R b , together with the nitrogen atom, represent a saturated or ethylenically unsaturated non-aromatic monocyclic heterocyclic group having 3-10 ring members or a saturated or unsaturated bicyclic heterocyclic group having up to 10 ring carbon atoms, the ring containing the nitrogen atom being non-aromatic and either saturated or ethylenically unsaturated, which heterocyclic groups may be unsubstituted or substituted by C 1-4 alkyl; the 17aα-hydrogen D-homo analogues thereof; and the acid addition salts thereof.
Claim 3
Dependent Claim 321 words
Compounds as claimed in claim 1, which compounds are of the formula: ##STR91## wherein: R 1 is as defined in claim 1; R 2 is a hydrogen atom or a methyl group; R 3 is a hydrogen atom or optionally, when R 4 is a hydrogen atom, a C 1-3 alkyl group; R 4 is a hydrogen atom or C 1-5 alkyl, C 1-5 alkoxy which may be substituted by a halogen atom or a phenyl group, C 2-5 alkanoyloxy, C 2-5 alkanoylthio, or thiocyanato group or a halogen atom; R 5 is a hydrogen atom or a methyl group; R 6 is a hydrogen atom or a methyl group; R 7 represents two hydrogen atoms; a hydrogen atom in the β-position and a chlorine atom or methyl group in the α-position; a methyl group in the β-position and a hydrogen atom in the α-position; or a gem-dimethyl group; and R 8 is a cyano group or a group --COR 9 where R 9 is a methyl group or a methyl group substituted by a fluorine atom, a C 1-4 alkoxy, hydroxy, methyl, chloromethyl, methoxymethyl, ethoxymethyl, C 2-5 alkanoyloxy, C 2-5 alkanoylthio, benzoyloxy, benzoylthio, or C 2-5 alkoxycarbonyloxy group; or where R 9 is a C 1-5 alkoxy, C 1-5 alkylthio or cyclopropyl group; or where R 9 is the group -NR x R y where R x and R y , which may be the same or different, are methyl or ethyl groups; the broken lines indicate the optional presence of double bonds at the positions shown; provided that R 3 and R 4 together represent a hydrogen atom when a 1,2-double bond is present; that the 2-position is saturated when a 4,5-double bond is present; and that the 6-position is saturated when a 8,9-double bond is present; and the D-homo analogues carrying R 8 at the 17aβ-position and R 7 at the 17-position; and the acid addition salts thereof.
Claim 4
Dependent Claim 15 words
Compounds as claimed in claim 1 said compounds being 20-oxo pregnanes or 20-oxo D-homo pregnanes.
Claim 5
Dependent Claim 54 words
Compounds as claimed in claim 1 which possess a 5α-hydrogen atom and 10-methyl group, which possess no carbon-carbon double bonds in the tetracyclic steroid system and possess hydrogen atoms at the 2α, 3β, 6β and 16-positions, in which ring D is a 5-membered ring, and which possess a 17β-acetyl group or are 17β-cyano androstanes.
Claim 6
Dependent Claim 21 words
Compounds as claimed in claim 1 wherein R 1 is an N-mono-or N,N-disubstituted aminomethyl, aminoethyl aminopropyl, aminobutyl, amino-iso-butyl or aminobenzyl group.
Claim 7
Dependent Claim 17 words
Compounds as claimed in claim 5 wherein R 1 is an N-mono-or N,N-disubstituted aminomethyl or 1-aminoethyl group.
Claim 8
Dependent Claim 58 words
Compounds as claimed in claim 2 in which R 1 is an N-mono- or N,N-disubstituted aminomethyl or 1-aminoethyl group and wherein R a and R b are both unsubstituted alkyl groups, which may be the same or different, or one of R a and R b is a hydrogen atom and the other is an unsubstituted alkyl group.
Claim 9
Dependent Claim 17 words
Compounds as claimed in claim 7 wherein R a and R b together contain 4-9 carbon atoms.
Claim 10
Dependent Claim 60 words
Compounds as claimed in claim 8 wherein R a and R b are both ethyl or propyl groups, or wherein one of R a and R b is a methyl or ethyl group and the other contains 4-6 carbon atoms, or wherein one of R a and R b is a hydrogen atom and the other contains 5-7 carbon atoms.
Claim 11
Dependent Claim 42 words
Compounds as claimed in claim 2 in which R 1 is an N,N-disubstituted aminomethyl or 1-aminoethyl group and wherein --NR a R b is a monocyclic heterocyclic group having 5-7 ring members, which may be unsubstituted or substituted by a methyl group.
Claim 12
Dependent Claim 22 words
Compounds as claimed in claim 10 wherein the heterocyclic group is a pyrrolidino, piperidino, hexamethylenimino or a 2-, 3- or 4-methylpiperidino group.
Claim 13
Dependent Claim 51 words
Compounds as claimed in claim 2 in which R 1 is an N-mono- or N,N-disubstituted aminomethyl or 1-aminomethyl group and wherein one of R a and R b is a hydrogen atom or a methyl or ethyl group, and the other is an allyl, cyclohexyl, cyclopentyl, cyclopropyl, benzyl or phenethyl group.
Claim 14
Dependent Claim 16 words
Compounds as claimed in claim 2 wherein R 1 is an N-mono- or N,N-disubstituted aminomethyl group.
Claim 15
Dependent Claim 16 words
Compounds as claimed in claim 2 which possess a 2β-hydrogen atom or C 1-5 alkoxy group.
Claim 16
Dependent Claim 31 words
Compounds as claimed in claim 1 in the form of their hydrochloride, hydrobromide, phosphate, sulphate, p-toluenesulphonate, methanesulphonate, citrate, tartrate, acetate, ascorbate, lactate, maleate, succinate, tricarballylate, glutarate, aconitate, citraconate or glutaconate salts.
Claim 17
Dependent Claim 17 words
Pharmaceutical compositions comprising a compound as claimed in claim 1, together with a pharmaceutical carrier or excipient.
Claim 18
Dependent Claim 18 words
A composition as claimed in claim 16 wherein said compound is in solution in a parenterally acceptable vehicle.
Claim 19
Dependent Claim 21 words
A composition as claimed in claim 17 in the form of a simple aqueous solution of a salt of said compound.
Claim 20
Dependent Claim 53 words
A process for the preparation of a compound as claimed in claim 1, which process comprises reaction of an amine HNR a R b , where R a and R b are as defined in claim 1, with a corresponding 11β-alkanoyloxy or 11β-aralkanoyloxy compound having a readily displaceable substituent in the alkyl portion.
Claim 21
Dependent Claim 53 words
11β-Halo esters of the pregnane and androstane series and their 19-nor and D-homo analogues having the structure as defined in claim 1 wherein R 1 is a C 1-6 alkyl group or a monocyclic aralkyl group having a C 1-6 alkyl portion, the alkyl group or portion being substituted by a halogen atom.
Claim 22
Dependent Claim 80 words
A compound as claimed in claim 1, wherein said compound is 11β-N,N-dipropylaminoacetoxy-3α-hydroxy-5α-pregnan-20-one, 11β-N,N-dipropylaminoacetoxy-3α-hydroxy-5α-pregnan-20-one phosphate, 11β-N,N-dipropylaminoacetoxy-3α-hydroxy-5α-pregnan-20-one citrate, 11β-N,N-dipropylaminoacetoxy-3α-hydroxy-5α-pregnan-20-one tricarballylate, 11β-N,N-dipropylaminoacetoxy-3α-hydroxy-5α-pregnan-20-one hydrochloride, 11β-N,N-dipropylaminoacetoxy-3α-hydroxy-5α-pregnan-20-one hemisulphate, 11β-dipropylaminoacetoxy-3α-hydroxy-5α-pregnan-20-one tartrate, 11β-N,N-dipropylaminoacetoxy-3α-hydroxy-5α-pregnan-20-one lactate and 11β-N,N-dipropylaminoacetoxy-3α-hydroxy-5α-pregnan-20-one glutarate, 11β-piperidinoacetoxy-3α-hydroxy-5α-pregnan-20-one, 11β-piperidinoacetoxy-3α-hydroxy-5α-pregnan-20-one citrate, 11β-piperidinoacetoxy-3α-hydroxy-5α-pregnan-20-one hydrochloride, 11β-(3-methylpiperidinoacetoxy)-3α-hydroxy-5α-pregnan-20-one, 11β-(3-methylpiperidinoacetoxy)-3α-hydroxy-5α-pregnan-20-one citrate, 11β-(4-methylpiperidinoacetoxy)-3α-hydroxy-5α-pregnan-20-one, 11β-(4-methylpiperidinoacetoxy)-3α-hydroxy-5α-pregnan-20-one citrate, 11β-(2-methylpiperidinoacetoxy)-3α-hydroxy-5α-pregnan-20-one, 11β-(2-methylpiperidinoacetoxy)-3α-hydroxy-5α-pregnan-20-one citrate, 11β-hexamethyleniminoacetoxy-3α-hydroxy-5α-pregnan-20-one, 11β-hexamethyleniminoacetoxy-3α-hydroxy-5α-pregnan-20-one citrate; 2β-ethoxy-11β-N,N-dipropylaminoacetoxy-3α-hydroxy-5α-pregnan-20-one, 2β-ethoxy-11β-N,N-dipropylaminoacetoxy-3α-hydroxy-5α-pregnan-20-one citrate, 2β-ethoxy-11β-N,N-dipropylaminoacetoxy-3α-hydroxy-5α-pregnan-20-one tricarballylate, 2β-methyl-11β-N,N-dipropylaminoacetoxy-3α-hydroxy-5α-pregnan-20-one, 2β-methyl-11β-N,N-dipropylaminoacetoxy-3α-hydroxy-5α-pregnan-20-one citrate, 2β-ethoxy-11β-N-methyl-N-butylaminoacetoxy-3α-hydroxy-5.alpha.-pregnan-20-one, 2β-ethoxy-11β-N-methyl-N-butylaminoacetoxy-3α-hydroxy-5.alpha.-pregnan-20-one citrate, 2β-propoxy-11β-N,N-diethylaminoacetoxy-3α-hydroxy-5α-pregnan-20-one, 2β-propoxy-11β-N,N-diethylaminoacetoxy-3α-hydroxy-5α-pregnan-20-one citrate; 3α-hydroxy-3β-methyl-11β-piperidinoacetoxy-5α-pregnan-20-one, 3α-hydroxy-3β-methyl-11β-piperidinoacetoxy-5α-pregnan-20-one citrate; 17β-cyano-3α-hydroxy-11β-N,N-dipropylaminoacetoxy-5α-androstane, 17β-cyano-3α-hydroxy-11β-N,N-dipropylaminoacetoxy-5α-androstane citrate; 3α-hydroxy-11β-N-methyl-N-1',3'-dimethylbutylaminoacetoxy-5.alpha.-pregnan-20-one, 3α-hydroxy-11β-N-methyl-N-1',3'-dimethylbutylaminoacetoxy-5.alpha.-pregnan-20-one citrate; 11β-N,N-diethylaminoacetoxy-3α-hydroxy-5α-pregnan-20-one, 11β-N,N-diethylaminoacetoxy-3α-hydroxy-5α-pregnan-20-one citrate; 2β-bromo-3α -hydroxy-11β-N-butyl-N-methylaminoacetoxy-5α-pregnan-20-one, 2β-bromo-3α-hydroxy-11β-N-butyl-N-methylaminoacetoxy-5.alpha.-pregnan-20-one citrate; 11β-N-butyl-N-methylaminoacetoxy-17β-cyano-3α-hydroxy-5.alpha.-androstane or 11β-N-butyl-N-methylaminoacetoxy-17β-cyano-3α-hydroxy-5.alpha.-androstane citrate.
Claim 23
Dependent Claim 24 words
A compound as claimed in claim 1, which is 11β-N,N diethylaminoacetoxy-2β-ethoxy-3α-hydroxy-5α-pregnan-20-one, 11β-N,N-diethylaminoacetoxy-2β-ethoxy-3α-hydroxy-5α-pregnan-20-one citrate; 11β-N-methyl-N-butylaminoacetoxy-3α-hydroxy-5α-pregnan-20-one, 11β-N-methyl-N-butylaminoacetoxy-3α-hydroxy-5α-pregnan-20-one citrate; 11β-N-ethyl-N-butylaminoacetoxy-3α-hydroxy-5α-pregnan-20-one, 11β-N-ethyl-N-butylaminoacetoxy-3α-hydroxy-5α-pregnan-20-one citrate, 11β-N-ethyl-N-butylaminoacetoxy-3α-hydroxy-5α-pregnan-20-one hydrochloride or 11β-N-ethyl-N-butylaminoacetoxy-3α-hydroxy-5α-pregnan-20-one tricarballylate.
Claim 24
Dependent Claim 50 words
A compound as claimed in claim 1, said compound being: 3α-hydroxy-11β-N-2'-methylbutylaminoacetoxy-5α-pregnan-20-one, 3α-hydroxy-11β-N-2'-methylbutylaminoacetoxy-5α-pregnan-20-one citrate; 3α-hydroxy-11β-N-methyl-N-2'-methylbutylaminoacetoxy-5α-pregnan-20-one, 3α-hydroxy-11β-N-methyl-N-2'-methylbutylaminoacetoxy-5α-pregnan-20-one citrate; 3α-hydroxy-11β-N-methyl-N-[(2R)-1',3'dimethylbutyl]aminoacetoxy-5α-pregnan-20-one, 3α-hydroxy-11β-N-methyl-N-[(2R)-1',3'-dimethylbutyl]aminoacetoxy-5α-pregnan-20-one citrate; 3α-hydroxy-11β-N-methyl-N-[(2S)-1',3'-dimethylbutyl]aminoacetoxy-5α-pregnan-20-one, 3α-hydroxy-11β-N-methyl-N-[(2S)-1',3'-dimethylbutyl]aminoacetoxy-5α-pregnan-20-one citrate; 11β-N,N-di(but-2-yl)aminoacetoxy-3α-hydroxy-5α-pregnan-20-one, 11β-N,N-di(but-2-yl)aminoacetoxy-3α-hydroxy-5α-pregnan-20-one citrate; 11β-N-1',3'-dimethylbutyl-N-ethylaminoacetoxy-3α-hydroxy-5.alpha.-pregnan-20-one, 11β-N-1',3'-dimethylbutyl-N-ethylaminoacetoxy-3α-hydroxy-5.alpha.-pregnan-20-one citrate; 11β-N-2',2'-dimethylpropylaminoacetoxy-3α-hydroxy-5α-pregnan-20-one, 11β-N-2'2'-dimethylpropylaminoacetoxy-3α-hydroxy-5α-pregnan-20-one citrate; 11β-N,N-diethylaminoacetoxy-3α-hydroxy-2β-methyl-5α-pregnan-20-one, 11β-N,N-diethylaminoacetoxy-3α-hydroxy-2β-methyl-5α-pregnan-20-one citrate; 11β-N-ethyl-N-butylaminoacetoxy-3α-hydroxy-2β-methyl-5.alpha.-pregnan-20-one, 11β-N-ethyl-N-butylaminoacetoxy-3α-hydroxy-2β-methyl-5.alpha.-pregnan-20-one citrate; 3α-hydroxy-2β-methyl-11β-(4'-methylpiperidinoacetoxy)-5.alpha.-pregnan-20-one, 3α-hydroxy-2β-methyl-11β-(4'methylpiperidinoacetoxy)-5.alpha.-pregnan-20-one citrate; 2β-ethoxy-3α-hydroxy-11β-N-3'-methylbutylaminoacetoxy-5.alpha.-pregnan-20-one, 2β-ethoxy-3α-hydroxy-11β-N-3'-methylbutylaminoacetoxy-5.alpha.-pregnan-20-one citrate; 2β-ethoxy-3α-hydroxy-11β-N-1',3'-dimethylbutylaminoacetoxy-5α-pregnan-20-one, 2β-ethoxy-3α-hydroxy-11β-N-1',3'-dimethylbutylaminoacetoxy-5α-pregnan-20-one citrate; 11β-N,N-diethylaminoacetoxy-3α-hydroxy-2β-iso-propoxy-5.alpha.-pregnan-20-one, or 11β-N,N-diethylaminoacetoxy-3α-hydroxy-2β-iso-propoxy-5.alpha.-pregnan-20-one citrate.

References Cited (Backward Citations)

US3943124A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1983-03-11 1983-09-10 1984-03-11 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1987-03-11 1987-09-10 1988-03-11 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1991-03-11 1991-09-10 1992-03-11 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag